AstraZeneca sticks to second-half 2015 timetable for new lung cancer pill

AstraZeneca sticks to second-half 2015 timetable for new lung cancer pill

MADRID (Reuters) - AstraZeneca said on Saturday it expected to file a new lung cancer pill for U.S. regulatory approval in the second half of 2015, potentially disappointing some investors who had hoped the drug might be ready faster. Analysts at Citi said in a research note this week they believed AZD9291 could be submitted as early as the first quarter of 2015, putting AstraZeneca ahead in a race with Clovis Oncology, which is developing a similar medicine. ...

Ebola clinics fill up as Liberia awaits aid

MONROVIA, Liberia (AP) — Fourteen-year-old D.J. Mulbah set off at dawn with his mother and grandmother in desperate pursuit of a coveted bed at the Ebola clinic run by Doctors Without Borders in Liberia's capital.

AstraZeneca sticks to second-half 2015 timetable for new lung cancer pill

MADRID (Reuters) - AstraZeneca said on Saturday it expected to file a new lung cancer pill for U.S. regulatory approval in the second half of 2015, potentially disappointing some investors who had hoped the drug might be ready faster. Analysts at Citi said in a research note this week they believed AZD9291 could be submitted as early as the first quarter of 2015, putting AstraZeneca ahead in a race with Clovis Oncology, which is developing a similar medicine. ...

Early data promising for AstraZeneca cancer drug combination

By Ben Hirschler MADRID (Reuters) - Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive. The British drugmaker, which fended off a $118 billion takeover bid from Pfizer in May in part by talking up its cancer drug prospects, has high hopes for the combination of two experimental drugs known as MEDI4736 and tremelimumab. ...

Watch: Dr. Besser Chats With Relief Workers Headed to Ebola Hot Zone

Plane taking relief workers to Liberia.

AstraZeneca sticks to second-half 2015 timetable for new lung cancer pill

MADRID (Reuters) - AstraZeneca said on Saturday it expected to file a new lung cancer pill for U.S. regulatory approval in the second half of 2015, potentially disappointing some investors who had hoped the drug might be ready faster. Analysts at Citi said in a research note this week they believed AZD9291 could be submitted as early as the first quarter of 2015, putting AstraZeneca ahead in a race with Clovis Oncology, which is developing a similar medicine. ...

Japanese volcano kills one, over 30 seriously injured

By Antoni Slodkowski and Mari Saito TOKYO (Reuters) - A Japanese volcano popular with hikers erupted on Saturday, killing one woman and seriously injuring more than 30 people, officials and media said. The mountain draws walkers who come to admire the autumn colors on the trees. "It was like thunder," a woman told public broadcaster NHK of the first eruption at the volcano in seven years. "I heard boom, boom, then everything went dark. ...

Ebola clinics fill up as Liberia awaits aid

MONROVIA, Liberia (AP) — Fourteen-year-old D.J. Mulbah set off at dawn with his mother and grandmother in desperate pursuit of a coveted bed at the Ebola clinic run by Doctors Without Borders in Liberia's capital.

Early data promising for AstraZeneca cancer drug combination

By Ben Hirschler MADRID (Reuters) - Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive. The British drugmaker, which fended off a $118 billion (72.64 billion pound) takeover bid from Pfizer in May in part by talking up its cancer drug prospects, has high hopes for the combination of two experimental drugs known as MEDI4736 and tremelimumab. ...

Pfizer drug effective in patients with rare lung cancer: study

By Bill Berkrot (Reuters) - Pfizer Inc's Xalkori, which treats lung cancer patients with a specific gene mutation, proved effective in shrinking tumors in those with an even rarer form of the disease, according to data presented at a medical meeting on Saturday. In the study of 50 non-small cell lung cancer patients with a rearrangement of the ROS1 gene, Xalkori treatment led to significant tumor shrinkage in 36 of them, or 72 percent, and halted tumor growth in an additional 9 patients, researchers reported. ...

You are reading an article about AstraZeneca sticks to second-half 2015 timetable for new lung cancer pill and you can find this article in url https://we-care-you.blogspot.com/2014/09/astrazeneca-sticks-to-second-half-2015.html,You can copy paste and use the article AstraZeneca sticks to second-half 2015 timetable for new lung cancer pill , may this is very interesting for you and others ,but don't forget to take this link AstraZeneca sticks to second-half 2015 timetable for new lung cancer pill for article source, Thanks.